dr. vogelzang discusses cabozantinib's dose size
Published 13 years ago • 365 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
1:35
dr. vogelzang discusses cabozantinib trial design
-
1:36
dr. vogelzang discusses mortalities in cabozantinib trial
-
1:34
dr. vogelzang discusses the cabozantinib trial design
-
1:14
dr. vogelzang describes cabozantinib's side effects
-
1:16
dr. ezra cohen discusses the cabozantinib dose size and tolerability
-
2:22
nicholas vogelzang, md, discusses re-emergence of dose reduced cabozantinib alezotuzumab in apc
-
0:56
dr. vogelzang on cabozantinib clinical trial results
-
0:59
dr. ezra cohen discusses the cabozantinib exam trial
-
1:11
dr. vogelzang on xl184's effect on bone metastases
-
1:41
dr. posadas discusses cabozantinib in prostate cancer
-
0:52
dr. choueiri on the role of cabozantinib in rcc
-
1:53
dr. nicholas vogelzang discusses sequencing abiraterone and enzalutamide
-
1:27
dr. ezra cohen on the efficacy and pharmacokinetics of cabozantinib
-
6:00
clinical rationale for cabozantinib in hcc
-
1:19
dr. agarwal on the safety of cabozantinib/atezolizumab in mcrpc
-
1:13
dr. agarwal on data with cabozantinib/atezolizumab in mcrpc
-
1:12
dr. vogelzang discusses mpdl3280a in patients with metastatic urothelial bladder cancer
-
1:46
what is the next big thing in kidney cancer care and treatment?
-
1:34
dr. eric sherman on the sequencing of cabozantinib and vandetanib for mtc